Brain Tumors Clinical Trial
Official title:
A Case-Referent Study of Brain Tumors in Adults
Verified date | February 26, 2018 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The etiology of brain tumors is poorly understood. Due, in part, to public concern about a
postulated relationship between the use of cellular telephones or other increasingly
prevalent environmental exposures and the incidence of brain cancer in adults, the National
Cancer Institute is collaborating with three U.S. hospitals in a comprehensive case-control
study of malignant and benign brain tumors. Factors under consideration include use of
cellular phones and other wireless communication devices, workplace exposures to chemical
agents and electromagnetic fields, dietary factors, family history of tumors, genetic
determinants of susceptibility, home appliance use, reproductive history and hormonal
exposures, viruses, medical and dental exposure to ionizing radiation, and other aspects of
medical history.
Approximately 800 newly diagnosed brain tumor cases and 800 controls have been enrolled at
hospitals in Boston, Phoenix and Pittsburgh. Cases include all adults (age greater than or
equal to 18 years) newly diagnosed with a histologically confirmed intracranial glioma,
intracranial meningioma or acoustic neuroma. Controls are patients admitted to the same
hospitals as the cases, and treated for any of a variety of non-malignant conditions.
Participating cases and controls were interviewed in the hospital by a research nurse and
asked to complete a self-administered questionnaire and donate a sample of blood. Key
features of the study include its large size, the emphasis on rapid ascertainment of incident
cases and interview of study subjects rather than surrogate respondents, the use of detailed,
job-specific questions developed by industrial hygienists to ascertain occupational
exposures, and the storage of blood samples for future evaluation of inherited
susceptibility, biomarkers of exposure and gene-environment interactions.
Implementation of the study protocol proceeded without serious problems. There have been no
harmful effects on study participants. There have been no complaints from participants or
breaches of confidentiality. Continuation of this research involves analysis and reporting of
results. As there will be many papers, this process is expected to extend over the next
several years.
Status | Completed |
Enrollment | 1581 |
Est. completion date | February 26, 2018 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 90 Years |
Eligibility |
- INCLUSION CRITERIA: Age greater than or equal to 18 years. Subjects with malignant and benign adult brain tumors from hospitals in Boston, Phoenix and Pittsburgh. INCLUSION CRITERIA - Controls: Patients admitted to the same hospitals as the cases, and treated for any of a variety of non-malignant conditions. EXCLUSION CRITERIA: Reasons for exclusion of cases included absense of histologic confirmation or ineligible diagnosis (e.g., schwannoma of facial or trigeminal nerve rather than of acoustic nerve). EXCLUSION CRITERIA - Controls: Controls were excluded if cancer was responsible for the hospital admission. |
Country | Name | City | State |
---|---|---|---|
United States | Brigham and Women's Hospital | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) | Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health (NIOSH/CDC) |
United States,
Brenner AV, Linet MS, Fine HA, Shapiro WR, Selker RG, Black PM, Inskip PD. History of allergies and autoimmune diseases and risk of brain tumors in adults. Int J Cancer. 2002 May 10;99(2):252-9. — View Citation
De Roos AJ, Stewart PA, Linet MS, Heineman EF, Dosemeci M, Wilcosky T, Shapiro WR, Selker RG, Fine HA, Black PM, Inskip PD. Occupation and the risk of adult glioma in the United States. Cancer Causes Control. 2003 Mar;14(2):139-50. — View Citation
Inskip PD, Tarone RE, Hatch EE, Wilcosky TC, Shapiro WR, Selker RG, Fine HA, Black PM, Loeffler JS, Linet MS. Cellular-telephone use and brain tumors. N Engl J Med. 2001 Jan 11;344(2):79-86. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Brain Tumor | 07/15/1994 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02846038 -
Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
|
||
Completed |
NCT02537106 -
A Comparison of the Effect of 1.5 Versus 3% NaCl on Brain Relaxation and Microcirculation
|
N/A | |
Completed |
NCT01951950 -
Nicardipine vs Esmolol Craniotomy Emergence
|
Phase 1 | |
Completed |
NCT01222780 -
To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer
|
Phase 1 | |
Completed |
NCT00873184 -
Study of Massage Therapy Within a Brain Tumor Setting
|
N/A | |
Active, not recruiting |
NCT01115777 -
Prospective Assessment of Quality of Life (QOL) in Pediatric Patients Treated With Radiation Therapy for Brain Tumors and Non-central Nervous System (Non-CNS) Malignancies
|
||
Completed |
NCT00724191 -
Evaluation of Human Brain Tumor Therapy Response by Magnetic Resonance (MR)
|
||
Completed |
NCT00003935 -
Combination Chemotherapy Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma
|
Phase 1 | |
Recruiting |
NCT04128306 -
Brain Areas of Time-To-Contact Perception: an Awake Surgery Study
|
N/A | |
Recruiting |
NCT05202899 -
Effect of Sugammadex for Reversal of Rocuronium-induced Neuromuscular Block on Perioperative Management of Awake Craniotomy
|
Phase 4 | |
Completed |
NCT00707343 -
[F-18] Fluorothymidine (FLT) Imaging on Patients With Primary Brain Tumors
|
Phase 1 | |
Completed |
NCT00850278 -
Assessment of [18F]FLT-PET Imaging for Diagnosis and Prognosis of Brain Tumors
|
N/A | |
Terminated |
NCT00107471 -
Topotecan, G-CSF, and Radiation Therapy in Treating Young Patients With Newly Diagnosed Brain Stem Glioma
|
Phase 1/Phase 2 | |
Completed |
NCT00528437 -
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
|
Phase 2 | |
Completed |
NCT00187174 -
Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors
|
Phase 1 | |
Completed |
NCT00135876 -
Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients
|
Phase 3 | |
Completed |
NCT00062478 -
Study of Karenitecin (BNP1350) in Patients With Brain Tumors
|
Phase 2 | |
Completed |
NCT00241670 -
Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid
|
Phase 3 | |
Not yet recruiting |
NCT01445691 -
More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery
|
Phase 2 | |
Terminated |
NCT01018290 -
Navigated Transcranial Magnetic Stimulation in Tumor Surgery
|
N/A |